On Monday, AstraZeneca Plc shared top-line results from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi. The trial, conducted in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs), did not meet the primary endpoint of overall survival (OS) compared to standard-of-care docetaxel. The participants had experienced disease progression after prior immunotherapy and platinum-based chemotherapy. The combination of ceralasertib and Imfinzi demonstrated good tolerability, with a safety profile consistent with both medicines' known profiles, and no new safety concerns arose. At the same time, AstraZeneca and Daiichi Sankyo Co., Ltd.'s Enhertu (trastuzumab deruxtecan) earned FDA Breakthrough Designation.